Fundz

Outro, a de-prescribing startup, raises $7M in pre-seed and seed funding to help patients safely discontinue antidepressants.

PRIVATEOct 08, 2026

Amount Raised

$7 Million

Round Type

Seed

BiotechnologyHealth CareMedical

Description

Outro, a de-prescribing startup, announced today that it has raised $7 million in pre-seed and seed funding. The company focuses on helping patients safely discontinue antidepressants by addressing withdrawal symptoms and providing structured tapering support. Outro employs healthcare professionals, including nurse practitioners like Kristen Massingill, who work with patients on medication reduction strategies. The funding will support the company's mission to improve the de-prescribing process and patient outcomes.

Quick answer

Outro raised $7 Million in a Seed round, dated October 8, 2026.

How much did Outro raise?
Outro raised $7 Million in a Seed round on October 8, 2026.
What does Outro do?
Outro is a de-prescribing startup that helps patients safely discontinue antidepressant medications through personalized tapering plans.

Source: Fundz verified event record.

Who else raised in Medical and Biotechnology around the same time

Companies in the same sectors as Outro that raised within 45 days of this round, from Fundz verified event records.

  • Skribe Medical raised $1.6M (Pre-Seed) on November 12, 2026.
  • Orakl Oncology raised $34M (Series A) on November 12, 2026.
  • EnVision Endoscopy raised $12M (Series A) on November 10, 2026.
  • Alterra Labs raised $13M (Seed) on November 10, 2026.
  • Alethio raised $90M (Series A) on November 5, 2026.
  • JawBuddy raised $917K (Pre-Seed) on November 4, 2026.

Who to call at Outro, and when

A new round usually means Outro is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Outro raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Outro, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Outro. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Outro

About

Outro is a de-prescribing startup that helps patients safely discontinue antidepressant medications through personalized tapering plans. The company works with healthcare practitioners to address withdrawal symptoms and provide tailored support during medication reduction. Outro was co-founded by psychiatry researcher Mark Horowitz and has raised $7 million in pre-seed and seed funding. The startup focuses on patient education and individualized approaches to antidepressant discontinuation.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Outro raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Outro's next move

See what Strategic adds

Outro raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.